Table 2.
The baseline descriptive statistics of the entire study population (aged 40–80 at start of cohort) contained in the Julius General Practice Network between 2014–2019
| Variable | Diabetes | No diabetes | P-value |
|---|---|---|---|
| N | 12,861 | 130,143 | |
| Age in years (SD) | 63.7 (10.3) | 55.1 (10.7) | < 0.001 |
| Female sex | 47.3% | 50.7% | < 0.001 |
| Comorbidities at baseline | |||
| Hypertension | 7379 (57.4%) | 25,484 (19.6%) | < 0.001 |
| Atrial fibrillation | 769 (6.0%) | 2791 (2.1%) | < 0.001 |
| Vascular disease | |||
| Peripheral artery disease | 923 (7.2%) | 2627 (2.0%) | < 0.001 |
| Any ischaemic heart disease/ angina pectoris | 2479 (19.3%) | 6601 (5.1%) | < 0.001 |
| Prior myocardial infarction | 1046 (8.1%) | 2844 (2.2%) | < 0.001 |
| Stroke | 647 (5.0%) | 2124 (1.6%) | < 0.001 |
| TIA | 462 (3.6%) | 1829 (1.4%) | < 0.001 |
| AAA | 494 (3.8%) | 1881 (1.4%) | < 0.001 |
| Heart failure | 767 (6.0%) | 1273 (1.0%) | < 0.001 |
| COPD | 1286 (10.0%) | 5342 (4.1%) | < 0.001 |
| Impaired glucose tolerance | NA | 1530 (1.2%) | |
| Medication use at baseline | |||
| Oral glucose lowering drugs | 9183 (71.4%) | NA | |
| Insulin | 2611 (20.3%) | NA | |
| Antithrombotics, total | 4073 (31.7%) | 11,909 (9.2%) | < 0.001 |
| Anticoagulants | 928 (7.2%) | 2785 (2.1%) | < 0.001 |
| Vitamin K antagonists | 911 (7.1%) | 2660 (2.0%) | < 0.001 |
| NOACs | 21 (0.2%) | 157 (0.1%) | 0.191 |
| Antiplatelet therapy | 3255 (25.3%) | 9022 (6.9%) | < 0.001 |
| Aspirin | 3112 (24.2%) | 8621 (6.6%) | < 0.001 |
| Clopidogrel | 299 (2.3%) | 812 (0.6%) | < 0.001 |
| Prasugrel, ticagrelor | 85 (0.7%) | 292 (0.2%) | < 0.001 |
| Diuretics | 4337 (33.7%) | 10,502 (8.1%) | < 0.001 |
| Beta-blockers | 4167 (32.4%) | 12,758 (9.9%) | < 0.001 |
| ACE-inhibitors/angiotensin-II-antagonists | 6893 (53.6%) | 14,515 (11.2%) | < 0.001 |
| Calcium channel antagonists | 2713 (21.1%) | 6020 (4.6%) | < 0.001 |
| Other antihypertensive drugs | 186 (1.4%) | 309 (0.2%) | < 0.001 |
| Thyroid drugs | |||
| Thyroid mimetics | 680 (5.3%) | 3373 (2.6%) | < 0.001 |
| Thyroid inhibitors | 20 (0.2%) | 165 (0.1%) | 0.387 |
| Lipid lowering drugs/statins | 8407 (65.4%) | 12,813 (9.8%) | < 0.001 |
| Antiarrhythmic drugs | |||
| Class I | 115 (0.9%) | 541 (0.4%) | < 0.001 |
| Class II | 4167 (32.4%) | 12,758 (9.9%) | < 0.001 |
| Class III | 52 (0.4%) | 145 (0.1%) | < 0.001 |
| Class IV | 2713 (21.1%) | 6020 (4.6%) | < 0.001 |
TIA: transient ischaemic attack; AAA: abdominal aortic aneurysm; COPD chronic obstructive pulmonary disease; NOAC: novel oral anticoagulant; ACE: angiotensin-converting enzyme; NA: not applicable